Language Selection

Français

Rabies Serum Neutralization Assay

<<Return to Laboratory

Accredited by the Standards Council of Canada to Laboratory no. 594 (ISO/IEC 17025)

Requisition Forms

Reference Details

Description:

Serology for detection of neutralizing antibodies to rabies virus.

Test Category:
Serology
Pathogen:
Rabies virus
Illnesses and Diseases:
  • Rabies
Specimen:

Serum sample, cerebrospinal fluid (CSF). Minimum volume required – 2 mL.

Collection Method:

Submit in a sterile microcentrifuge tube.

Specimen Processing, Storage and Shipping:

Store samples refrigerated or frozen until shipped for testing. Ship frozen samples on dry ice, and refrigerated samples on wet ice

Transportation of Dangerous Goods:

Shipping of specimens shall be done by a TDG certified individual in accordance with TDG regulations. For additional information regarding classification of specimens for the purposes of shipping, consult either Part 2 Appendix 3 of the TDG Regulations or section 3.6.2 of the IATA Dangerous Goods Regulations as applicable.

 

Patient Criteria:

Individuals who have received pre- or post-exposure vaccination for rabies virus. The Rabies, Rickettsia and Related Zoonotic Diseases laboratory must be notified prior to the submission of any samples for clinical investigation.

Accompanying Documentation:

Completed Rabies Serum Neutralization Assay requisition including sender name, address and telephone number. Patient name or identifier (referring lab #), date of birth, occupational category, vaccination history, administration of RIG, animal exposure, travel history. Type of specimen and date collected.

Comments:

Samples for post exposure vaccination will not be tested unless all requested information is supplied. The Rabies, Rickettsia and Related Zoonotic Diseases laboratory must be notified prior to the submission of any samples for clinical investigation.

Methods and Interpretation of Results:

Neutralizing antibody titres are reported in International Units/ml (IU/ml). Booster vaccination is recommended if antibody titre falls below 0.5 IU/ml. Individuals with antibody levels between 0.5 IU/ml and 1.0 IU/ml should be carefully assessed for their risk of exposure; if a booster dose of vaccine is not administered, a new serum sample should be drawn and tested within 3-6 months to ensure that the individual's antibody level does not fall below 0.5 IU/ml.

Turnaround Time:

30 calendar days.

Contact:
Phone #: (204) 789-7037
Fax: (204) 789-2018
References:
  1. Statement on travellers and rabies vaccine. Canada Communicable Disease Report. 2002; 28: 1-12.
Related Information: